VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Gilead Sciences, Inc. vs The Charles Schwab Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisThe Charles Schwab Corporation
SCHW · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into The Charles Schwab Corporation's moat claims, evidence, and risks.
View SCHW analysisComparison highlights
- Moat score: both at 74 / 100.
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); The Charles Schwab Corporation has 2 segments (79.4% in Investor Services).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Weak.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; The Charles Schwab Corporation has 7 across 4.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
The Charles Schwab Corporation
Investor Services
U.S. retail brokerage, self-directed investing, and wealth management platforms
United States
Retail investors, employers, retirement plan sponsors
Broker-dealer + bank + wealth manager platform
79.4%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
The Charles Schwab Corporation strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
The Charles Schwab Corporation segments
Full profile >Investor Services
Oligopoly
Advisor Services
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.